Cargando…

Efficacy and Clinical Determinants of Antipsychotic Polypharmacy in Psychotic Patients Experiencing an Acute Relapse and Admitted to Hospital Stay: Results from a Cross-Sectional and a Subsequent Longitudinal Pilot Study

Background. Antipsychotic polypharmacy is used in several psychiatric disorders, despite poor evidence existing to support this practice. Aim. We evaluated whether psychotic patients in acute relapse exposed to antipsychotic polypharmacy (AP + AP) showed different demographic, clinical, or psychopat...

Descripción completa

Detalles Bibliográficos
Autores principales: Iasevoli, Felice, Buonaguro, Elisabetta F., Marconi, Massimo, Di Giovambattista, Emanuela, Rapagnani, Maria Paola, De Berardis, Domenico, Martinotti, Giovanni, Mazza, Monica, Balletta, Raffaele, Serroni, Nicola, Di Giannantonio, Massimo, de Bartolomeis, Andrea, Valchera, Alessandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3921985/
https://www.ncbi.nlm.nih.gov/pubmed/24592333
http://dx.doi.org/10.1155/2014/762127
_version_ 1782303388793307136
author Iasevoli, Felice
Buonaguro, Elisabetta F.
Marconi, Massimo
Di Giovambattista, Emanuela
Rapagnani, Maria Paola
De Berardis, Domenico
Martinotti, Giovanni
Mazza, Monica
Balletta, Raffaele
Serroni, Nicola
Di Giannantonio, Massimo
de Bartolomeis, Andrea
Valchera, Alessandro
author_facet Iasevoli, Felice
Buonaguro, Elisabetta F.
Marconi, Massimo
Di Giovambattista, Emanuela
Rapagnani, Maria Paola
De Berardis, Domenico
Martinotti, Giovanni
Mazza, Monica
Balletta, Raffaele
Serroni, Nicola
Di Giannantonio, Massimo
de Bartolomeis, Andrea
Valchera, Alessandro
author_sort Iasevoli, Felice
collection PubMed
description Background. Antipsychotic polypharmacy is used in several psychiatric disorders, despite poor evidence existing to support this practice. Aim. We evaluated whether psychotic patients in acute relapse exposed to antipsychotic polypharmacy (AP + AP) showed different demographic, clinical, or psychopathological features compared to those exposed to one antipsychotic (AP) and whether AP + AP patients showed significantly higher improvement compared to AP patients after a 4-week treatment. Methods. Inpatients were subdivided into AP + AP and AP ones. In the cross-sectional step, patients were compared according to demographics, clinical variables, and scores on rating scales. In the longitudinal step, patients remained for 4 weeks under admission medications and were compared for clinical improvement. Results. AP + AP patients were more frequently diagnosed with schizophrenia and mental retardation as a comorbid illness. AP + AP patients were more frequently under first-generation antipsychotics and had worse clinical presentation. After 4 weeks of treatment, both AP + AP and AP patients improved compared to the baseline. However, AP patients scored significantly less than AP + AP patients at the Clinical Global Impression Scale at the 4-week time point but not at the baseline, indicating a treatment-specific improvement. Conclusions. Antipsychotic polypharmacy may be offered to specific types of psychotic patients. However, efficacy of this strategy is limited at best.
format Online
Article
Text
id pubmed-3921985
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-39219852014-03-03 Efficacy and Clinical Determinants of Antipsychotic Polypharmacy in Psychotic Patients Experiencing an Acute Relapse and Admitted to Hospital Stay: Results from a Cross-Sectional and a Subsequent Longitudinal Pilot Study Iasevoli, Felice Buonaguro, Elisabetta F. Marconi, Massimo Di Giovambattista, Emanuela Rapagnani, Maria Paola De Berardis, Domenico Martinotti, Giovanni Mazza, Monica Balletta, Raffaele Serroni, Nicola Di Giannantonio, Massimo de Bartolomeis, Andrea Valchera, Alessandro ISRN Pharmacol Clinical Study Background. Antipsychotic polypharmacy is used in several psychiatric disorders, despite poor evidence existing to support this practice. Aim. We evaluated whether psychotic patients in acute relapse exposed to antipsychotic polypharmacy (AP + AP) showed different demographic, clinical, or psychopathological features compared to those exposed to one antipsychotic (AP) and whether AP + AP patients showed significantly higher improvement compared to AP patients after a 4-week treatment. Methods. Inpatients were subdivided into AP + AP and AP ones. In the cross-sectional step, patients were compared according to demographics, clinical variables, and scores on rating scales. In the longitudinal step, patients remained for 4 weeks under admission medications and were compared for clinical improvement. Results. AP + AP patients were more frequently diagnosed with schizophrenia and mental retardation as a comorbid illness. AP + AP patients were more frequently under first-generation antipsychotics and had worse clinical presentation. After 4 weeks of treatment, both AP + AP and AP patients improved compared to the baseline. However, AP patients scored significantly less than AP + AP patients at the Clinical Global Impression Scale at the 4-week time point but not at the baseline, indicating a treatment-specific improvement. Conclusions. Antipsychotic polypharmacy may be offered to specific types of psychotic patients. However, efficacy of this strategy is limited at best. Hindawi Publishing Corporation 2014-01-27 /pmc/articles/PMC3921985/ /pubmed/24592333 http://dx.doi.org/10.1155/2014/762127 Text en Copyright © 2014 Felice Iasevoli et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Study
Iasevoli, Felice
Buonaguro, Elisabetta F.
Marconi, Massimo
Di Giovambattista, Emanuela
Rapagnani, Maria Paola
De Berardis, Domenico
Martinotti, Giovanni
Mazza, Monica
Balletta, Raffaele
Serroni, Nicola
Di Giannantonio, Massimo
de Bartolomeis, Andrea
Valchera, Alessandro
Efficacy and Clinical Determinants of Antipsychotic Polypharmacy in Psychotic Patients Experiencing an Acute Relapse and Admitted to Hospital Stay: Results from a Cross-Sectional and a Subsequent Longitudinal Pilot Study
title Efficacy and Clinical Determinants of Antipsychotic Polypharmacy in Psychotic Patients Experiencing an Acute Relapse and Admitted to Hospital Stay: Results from a Cross-Sectional and a Subsequent Longitudinal Pilot Study
title_full Efficacy and Clinical Determinants of Antipsychotic Polypharmacy in Psychotic Patients Experiencing an Acute Relapse and Admitted to Hospital Stay: Results from a Cross-Sectional and a Subsequent Longitudinal Pilot Study
title_fullStr Efficacy and Clinical Determinants of Antipsychotic Polypharmacy in Psychotic Patients Experiencing an Acute Relapse and Admitted to Hospital Stay: Results from a Cross-Sectional and a Subsequent Longitudinal Pilot Study
title_full_unstemmed Efficacy and Clinical Determinants of Antipsychotic Polypharmacy in Psychotic Patients Experiencing an Acute Relapse and Admitted to Hospital Stay: Results from a Cross-Sectional and a Subsequent Longitudinal Pilot Study
title_short Efficacy and Clinical Determinants of Antipsychotic Polypharmacy in Psychotic Patients Experiencing an Acute Relapse and Admitted to Hospital Stay: Results from a Cross-Sectional and a Subsequent Longitudinal Pilot Study
title_sort efficacy and clinical determinants of antipsychotic polypharmacy in psychotic patients experiencing an acute relapse and admitted to hospital stay: results from a cross-sectional and a subsequent longitudinal pilot study
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3921985/
https://www.ncbi.nlm.nih.gov/pubmed/24592333
http://dx.doi.org/10.1155/2014/762127
work_keys_str_mv AT iasevolifelice efficacyandclinicaldeterminantsofantipsychoticpolypharmacyinpsychoticpatientsexperiencinganacuterelapseandadmittedtohospitalstayresultsfromacrosssectionalandasubsequentlongitudinalpilotstudy
AT buonaguroelisabettaf efficacyandclinicaldeterminantsofantipsychoticpolypharmacyinpsychoticpatientsexperiencinganacuterelapseandadmittedtohospitalstayresultsfromacrosssectionalandasubsequentlongitudinalpilotstudy
AT marconimassimo efficacyandclinicaldeterminantsofantipsychoticpolypharmacyinpsychoticpatientsexperiencinganacuterelapseandadmittedtohospitalstayresultsfromacrosssectionalandasubsequentlongitudinalpilotstudy
AT digiovambattistaemanuela efficacyandclinicaldeterminantsofantipsychoticpolypharmacyinpsychoticpatientsexperiencinganacuterelapseandadmittedtohospitalstayresultsfromacrosssectionalandasubsequentlongitudinalpilotstudy
AT rapagnanimariapaola efficacyandclinicaldeterminantsofantipsychoticpolypharmacyinpsychoticpatientsexperiencinganacuterelapseandadmittedtohospitalstayresultsfromacrosssectionalandasubsequentlongitudinalpilotstudy
AT deberardisdomenico efficacyandclinicaldeterminantsofantipsychoticpolypharmacyinpsychoticpatientsexperiencinganacuterelapseandadmittedtohospitalstayresultsfromacrosssectionalandasubsequentlongitudinalpilotstudy
AT martinottigiovanni efficacyandclinicaldeterminantsofantipsychoticpolypharmacyinpsychoticpatientsexperiencinganacuterelapseandadmittedtohospitalstayresultsfromacrosssectionalandasubsequentlongitudinalpilotstudy
AT mazzamonica efficacyandclinicaldeterminantsofantipsychoticpolypharmacyinpsychoticpatientsexperiencinganacuterelapseandadmittedtohospitalstayresultsfromacrosssectionalandasubsequentlongitudinalpilotstudy
AT ballettaraffaele efficacyandclinicaldeterminantsofantipsychoticpolypharmacyinpsychoticpatientsexperiencinganacuterelapseandadmittedtohospitalstayresultsfromacrosssectionalandasubsequentlongitudinalpilotstudy
AT serroninicola efficacyandclinicaldeterminantsofantipsychoticpolypharmacyinpsychoticpatientsexperiencinganacuterelapseandadmittedtohospitalstayresultsfromacrosssectionalandasubsequentlongitudinalpilotstudy
AT digiannantoniomassimo efficacyandclinicaldeterminantsofantipsychoticpolypharmacyinpsychoticpatientsexperiencinganacuterelapseandadmittedtohospitalstayresultsfromacrosssectionalandasubsequentlongitudinalpilotstudy
AT debartolomeisandrea efficacyandclinicaldeterminantsofantipsychoticpolypharmacyinpsychoticpatientsexperiencinganacuterelapseandadmittedtohospitalstayresultsfromacrosssectionalandasubsequentlongitudinalpilotstudy
AT valcheraalessandro efficacyandclinicaldeterminantsofantipsychoticpolypharmacyinpsychoticpatientsexperiencinganacuterelapseandadmittedtohospitalstayresultsfromacrosssectionalandasubsequentlongitudinalpilotstudy